Sangart raises $50 million
This article was originally published in Scrip
Sangart has secured $50 million from investors in a series F financing round. The US company will use the proceeds to further the clinical development of its MP4 oxygen therapeutics pipeline. The privately held firm's lead candidate MP4OX combines a unique polyethylene glycol conjugation with human haemoglobin. The candidate is designed with optimal molecular size, viscosity, oxygen affinity and diffusion potential to target tissues with oxygen deprivation in artificial capillaries and animal models. The latest investment brings the total amount invested in the series F round to $100 million.